Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Speciality Medi.
Quarter-by-quarter operating performance
Financials of Speciality Medi.
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 40 | 23 | 28 | 58 | 75 |
| Expenses + | 38 | 20 | 22 | 49 | 62 |
| Operating Profit | 2 | 4 | 5 | 9 | 14 |
| OPM % | 6% | 15% | 19% | 16% | 18% |
| Other Income + | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 3 | 5 | 9 | 13 |
| Tax % | 31% | 43% | 36% | 1% | -0% |
| Net Profit + | 1 | 2 | 3 | 9 | 13 |
| EPS in Rs | 70.48 | 4.42 | 5.73 | 13.38 | 14.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Speciality Medi.
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.21 | 4 | 5 | 6 | 9 |
| Reserves | 2 | 2 | 10 | 24 | 62 |
| Borrowings + | 1 | 4 | 3 | 5 | 7 |
| Other Liabilities + | 3 | 4 | 5 | 5 | 17 |
| Total Liabilities | 6 | 13 | 23 | 40 | 95 |
| Fixed Assets + | 2 | 2 | 1 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 4 | 11 | 21 | 38 | 93 |
| Total Assets | 6 | 13 | 23 | 40 | 95 |
Financials of Speciality Medi.
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 1 | -4 | -5 | -6 | |
| Cash from Investing Activity + | -2 | 0 | -0 | -2 | |
| Cash from Financing Activity + | 2 | 4 | 5 | 8 | |
| Net Cash Flow | 0 | 0 | -0 | 1 | |
| Free Cash Flow | -1 | -4 | -5 | -6 | |
| CFO/OP | 36% | -101% | -66% | -63% |
Financials of Speciality Medi.
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 23 | 87 | 142 | 60 | 128 |
| Inventory Days | 5 | 103 | 161 | 150 | 191 |
| Days Payable | 12 | 40 | 48 | 8 | 80 |
| Cash Conversion Cycle | 16 | 149 | 255 | 202 | 239 |
| Working Capital Days | -3 | 76 | 185 | 180 | 221 |
| ROCE % | 52% | 38% | 34% | 25% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…